A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Clinical trial NCT03219450 · RECRUITING

Trial details

NCT number: NCT03219450
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphocytic Leukemia

Start date: 2021-08-18
Primary completion: 2027-07-31
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.